Quality & complianceOfficial

Dutch inspectorate publishes report on April 2026 visit to Asclepius Pharma in Bussum

🇳🇱 IGJ · Fri 06 Nov 2026

The IGJ has released a supervisory inspection report on Asclepius Pharma BV, but the material available gives no details of its findings or any required corrective measures.

The Dutch Health and Youth Care Inspectorate (IGJ) has published an inspection report on Asclepius Pharma BV, a company based in Bussum. The report stems from a supervisory visit carried out in April 2026 and was listed among the inspectorate's supervisory documents on 6 November 2026.

According to the information available, the report sets out the inspectorate's assessment and any improvement measures it requires. The text provided, however, contains only the page heading and no findings, so the outcome of the visit is not known from this source.

It is also unclear from the material which regulated activity the inspection covered, for example pharmacovigilance, good manufacturing practice or good distribution practice. Nor does the source say whether any deficiencies were identified or whether follow-up action was required.

As general context, inspectorates in Europe typically publish such reports to document the result of a supervisory visit and any corrective actions the company must take. Readers will need to consult the full IGJ report for the substance.

What it means for your team

  • Compliance teams with links to Asclepius Pharma, such as partners, suppliers or customers, should read the full IGJ report before drawing conclusions.
  • No findings, classification or required measures can be inferred from the information available so far.
  • The publication date of 6 November 2026 and the April 2026 visit date are the only confirmed details, so any relevance to PV, GMP or GDP must be checked in the report itself.

Official source: IGJ ↗

Article written by VigiEye from the official source (IGJ). AI-assisted; check the source before acting.

More Quality & compliance All →